Rheumatoid Arthritis
2nd Edition
Published on 20. July 2006
Book
Hardback
594 pages
978-0-19-856630-4 (ISBN)
Description
Rheumatoid arthritis (RA) is a chronic inflammatory disease, which affects 1% of the world's population. Patients with RA not only have a progressive and debilitating disease and severe functional impairment, but can also experience a reduced life expectancy due to frequent involvement of the major organ systems. This new edition of Rheumatoid Arthritis charts the profound changes in research and patient management that have taken place over the last 5 years.
Developments in molecular biology have dramatically increased insight into the inflammatory and destructive pathways of this complex disease. Over half a million patients have been successfully treated with biologic therapy and advances in imaging techniques have allowed increasingly early detection of
disease onset. Rheumatoid factor is no longer the unchallenged gold standard autoantibody but has competition from the anti-citrulline antibodies. Environmental factors influencing both susceptibility and progression have been sought, and smoking has emerged as a powerful factor. Steady progress in genetics is finally being made and one day it may be possible to predict RA before onset of symptomatic disease.
It is against this backdrop of dynamic developments that the new edition of Rheumatoid Arthritis publishes.
Developments in molecular biology have dramatically increased insight into the inflammatory and destructive pathways of this complex disease. Over half a million patients have been successfully treated with biologic therapy and advances in imaging techniques have allowed increasingly early detection of
disease onset. Rheumatoid factor is no longer the unchallenged gold standard autoantibody but has competition from the anti-citrulline antibodies. Environmental factors influencing both susceptibility and progression have been sought, and smoking has emerged as a powerful factor. Steady progress in genetics is finally being made and one day it may be possible to predict RA before onset of symptomatic disease.
It is against this backdrop of dynamic developments that the new edition of Rheumatoid Arthritis publishes.
Reviews / Votes
The new edition of this textbook certainly deserves a place on the shelf in each rheumatology office. * Rheumatology, Vol 46, * This comprehensive, new edition of Rheumatoid Arthritis has been extensively updated and extended. This is an excellent reference book which I would recommend for all rheumatology departments. * British Health Professionals in Rheumatology *More details
Edition
2nd Revised edition
Language
English
Place of publication
Oxford
United Kingdom
Target group
Professional and scholarly
Edition type
Revised edition
Illustrations
8 pp colour plate section + 220 b&w illustrations
Dimensions
Height: 284 mm
Width: 227 mm
Thickness: 33 mm
Weight
1985 gr
ISBN-13
978-0-19-856630-4 (9780198566304)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Previous edition
Gary S. Firestein | Gabriel S. Panayi | Frank A. Wollheim
Rheumatoid Arthritis
New Frontiers in Pathogenesis and Treatment
Book
08/2000
Oxford University Press
€179.81
Article exhausted; check for reprint
Persons
Content
Preface ; SECTION 1 ; Etiology ; 1. Genetics of rheumatoid arthritis ; 2. Epidemiology and determinants of susceptibility ; 3. Microbes in the pathogenesis of rheumatoid arthritis ; 4. Experimental models for rheumatoid arthritis ; SECTION 2 ; Mechanisms of inflammation ; 5. The role of macrophages in rheumatoid arthitis ; 6. The role of T lymphocytes in rheumatoid arthritis ; 7. The role of neutrophils in the pathogenesis of rheumatoid arthritis ; 8. The role of fibroblast-like synoviocytes in rheumatoid arthritis ; 9. The roles of B cells in rheumatoid arthritis ; 10. Innate immunity and immune complexes in rheumatoid arthritis ; 11. Angiogenesis and cell trafficking ; 12. Cytokine networks ; 13. Autoantibodies in rheumatoid arthritis ; 14. Mechanisms of fibroblast-mediated joint destruction ; 15. Pain mechanisms in rheumatoid arthritis ; 16. The stress system and the hypothalamic-pituitary adrenal (HPA) axis in rheumatoid arthritis ; SECTION 3 ; Clinical Aspects ; 17. Examination of the synovium and synovial fluid ; 18. Clinical aspects of rheumatoid arthritis ; 19. Imaging in rheumatoid arthritis ; 20. Susceptibility, prognosis & mortality ; 21. Biomarkers for cartilage and bone in rheumatoid arthritis ; SECTION 4 ; Drug Therapy ; 22. NSAIDS and analgesics ; 23. Systemic and intra-articular glucorticoids in rheumatoid arthritis ; 24. Methotrexate and Leflunomide ; 25. Gold, antimalarials, sulfasalazine, and other DMARDS ; 26. Combination therapy with synthetic DMARDs in the treatment of rheumatoid arthritis ; 27. Biologics in the treatment of rheumatoid arthritis ; SECTION 5 ; Non-Drug Therapy ; 28. The impact of physiotherapy ; 29. Patient Education ; 30. Occupation therapy and assistive products and technology ; 31. Psychological and social aspects ; 32. Pain management ; 33. Health economics ; SECTION 6 ; Surgical Therapy ; 34. Large joints and feet ; 35. The hand ; 36. The cervical spine ; SECTION 7 ; Frontiers of Therapy ; 37. Design of trials involving clinical endpoints ; 38. Clinical trials with imaging and biomark endpoints ; 39. New biologics: cytokines ; 40. New biologics: T and B cell modulators ; 41. Inhibibition of proteolytic activity involved in cartilage breakdown ; 42. Signal transduction in rheumatic diseases ; 43. Mesenchymal stem cells in arthritis